Ospraie-backed Marrone Bio’s new CEO targets rapid revenue growth

Kevin Helash says he expects consolidation among biologicals producers to gather pace in the next 12-24 months, as investors focus on strengthening the sub-sector’s early leaders.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this